When does this change take effect?

This change is effective Apr 1, 2026.

CommercialAdministrativeLow impact

06.02.26e, In Vitro Allergy Testing

Q: Who is affected by this change?

This affects Independence Blue Cross Allergy & Immunology, Internal Medicine, Family Medicine, Pediatrics providers on Commercial plans.

Independence Blue Cross·Allergy & Immunology, Internal Medicine, Family Medicine +1 more·Medical Policy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

The In Vitro Allergy Testing policy (06.02.26e) has been reissued for commercial plans effective April 1, 2026. This appears to be a routine policy reissuance rather than a substantive change to coverage or billing requirements.

Action Required

Action needed

By April 1, 2026: Review the updated In Vitro Allergy Testing policy on the IBX website to identify any changes to coverage criteria, prior authorization requirements, or billing guidelines. Billing team should verify current procedures align with reissued policy requirements.

Related policy hubs

Independence Blue Cross policies Allergy & Immunology Internal Medicine Family Medicine Pediatrics